GlassScriptPhysician profile
Julio Jorge
NPI 1861441156
$3,641.74
in general payments reported to CMS, 2019-2025
23 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,666 · 2020: $283 · 2022: $142 · 2023: $369 · 2024: $721 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $880.71 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $478.35 | 2019 | |
| Novo Nordisk INC | $412.02 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $322.01 | 2019-2025 | Airsupra |
| Amarin Pharma, INC. | $171.78 | 2019-2020 | |
| Edwards Lifesciences Corporation | $164.05 | 2024 | |
| Ethicon INC. | $154.69 | 2024 | Monarch Platform |
| Pfizer INC. | $141.91 | 2019-2025 | |
| Abbvie INC. | $124.99 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $124.94 | 2019-2025 | Zoryve |
| Ironwood Pharmaceuticals, INC | $121.43 | 2019 | |
| Astellas Pharma US INC | $96.57 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.37 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $81.70 | 2019-2023 | Mounjaro, Jardiance |
| Amgen INC. | $60.93 | 2022-2025 | Uplizna, Repatha, Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.53 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.98 | 2024 | |
| Abbott Laboratories | $37.45 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Allergan, INC. | $28.53 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.46 | 2022 | |
| Endo Pharmaceuticals INC. | $16.67 | 2019 | |
| Merck Sharp & Dohme LLC | $16.60 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.07 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Jorge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.